LANTERN PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.33 USD | +2.26% |
|
-2.31% | +47.90% |
| 05-09 | Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-09 | Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chart calendar Lantern Pharma Inc.
a012a36ccf3f6f2d1.sIEseRKYebx-5NY_JtzTPIEzqJfDNCkO2HaAVzQxqCg.ifJAMXH0Jo9GlOcOQOyfedNwx9qiQlNZlxv3PwYG32fj2WcBf-pK2jyesQ~1e78bbe3f9ab8ba0df6f917641abab9c
Upcoming events on Lantern Pharma Inc.
Past events on Lantern Pharma Inc.
| 2024-05-09 16:30 | Q1 2024 Earnings Call |
| 2024-05-09 16:02 | Q1 2024 Earnings Release |
| 2024-03-19 | Rare Disease Summit |
| 2024-03-18 16:30 | Q4 2023 Earnings Call |
| 2024-03-18 16:02 | Q4 2023 Earnings Release |
| 2024-03-07 14:00 | H.C. Wainwright Artificial Intelligence Based Drug Discovery & Development Virtual Conference - Fire |
| 2023-12-05 13:30 | CNS Drug Delivery Summit |
| 2023-12-01 01:30 | Bengaluru Tech Summit |
| 2023-11-17 13:55 | Society for Neuro Oncology Meeting |
| 2023-11-08 16:30 | Q3 2023 Earnings Call |
| 2023-11-08 16:01 | Q3 2023 Earnings Release |
| 2023-10-19 13:30 | ThinkEquity Conference |
| 2023-09-06 19:00 | Society of Hematologic Oncology Meeting - Poster Number: ABCL-180 |
| 2023-08-24 03:45 | Drug Conjugates for Directed Therapy International Conference |
| 2023-08-10 20:30 | American Society of Clinical Oncology CNS Cancer Conference |
| 2023-08-09 16:30 | Q2 2023 Earnings Call |
| 2023-08-09 16:01 | Q2 2023 Earnings Release |
| 2023-07-22 | Cancer Molecular Therapeutics Research Association Conference |
| 2023-07-16 | Biotech CEO Summit |
| 2023-06-16 11:00 | Annual General Meeting |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -12,6 -13,3 5.38% | -13,2 -14,5 8.72% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -5,91 -5,84 -1.13% | -12,6 -13,6 7.73% | -14,4 -16,1 10.52% | -17,9 -17,8 -0.49% | -25,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -5,91 -5,81 -1.66% | -12,4 -13,2 6.24% | -14,3 -16,3 12.42% | -16,0 -16,1 1% | -24,8 |
|
Net income Million USD | Released Forecast Spread | -5,91 -5,81 -1.66% | -12,4 -13,2 6.24% | -14,3 -16,2 12.01% | -16,0 -16,4 2.96% | -24,8 |
|
EPS USD | Released Forecast Spread | -1,37 -1,35 -1.48% | -1,13 -1,21 6.22% | -1,31 -1,48 11.49% | -1,47 -1,51 2.43% | -2,30 |
| Announcement Date | 10/03/21 | 10/03/22 | 20/03/23 | 18/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -4,06 -3,60 -12.9% | -1,84 -4,40 58.15% | -3,49 -4,70 25.67% | -3,95 -5,00 21.01% | -4,79 -5,30 9.54% | |||||||
|
EBIT Million USD | Released Forecast Spread | -4,07 -3,60 -12.96% | -4,39 -5,65 22.17% | -2,15 -5,30 59.53% | -3,83 -5,19 26.29% | -4,29 -5,30 19.13% | -5,19 -4,91 -5.69% | -3,52 -5,15 31.51% | -4,88 -4,63 -5.24% | -5,73 -5,40 -6.15% | -6,20 | -6,59 | -7,05 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -4,12 -3,20 -28.81% | -4,49 -5,63 20.19% | -2,26 -5,24 56.81% | -3,38 -5,14 34.16% | -3,87 -5,20 25.62% | -4,75 -4,74 -0.19% | -3,16 -4,94 35.94% | -4,19 -4,33 3.43% | -5,44 -4,70 -15.76% | -5,97 | -6,44 | -6,93 |
|
Net income Million USD | Released Forecast Spread | -4,12 -3,20 -28.81% | -4,49 -5,63 20.19% | -2,26 -5,24 56.81% | -3,38 -5,14 34.16% | -3,87 -5,20 25.62% | -4,75 -4,74 -0.19% | -3,16 -4,94 35.94% | -4,19 -4,33 3.43% | -5,44 -4,70 -15.76% | -5,97 | -6,44 | -6,93 |
|
EPS USD | Released Forecast Spread | -0,38 -0,29 -31.03% | -0,41 -0,52 21.15% | -0,21 -0,48 56.25% | -0,31 -0,47 34.04% | -0,36 -0,48 25% | -0,44 -0,43 -1.54% | -0,29 -0,46 36.26% | -0,38 -0,40 5% | -0,51 -0,43 -18.6% | -0,56 | -0,60 | -0,64 |
| Announcement Date | 03/05/22 | 08/08/22 | 07/11/22 | 20/03/23 | 09/05/23 | 09/08/23 | 08/11/23 | 18/03/24 | 09/05/24 | - | - | - |
| 2024-05-17 02:00 | BIOARCTIC AB: Q1 2024 Earnings Release |
| 2024-05-20 | ALVOTECH: Q1 2024 Earnings Release |
| 2024-05-21 | CUREVAC N.V.: Q1 2024 Earnings Release (Projected) |
| 2024-05-21 | EXSCIENTIA PLC: Q1 2024 Earnings Release (Projected) |
| 2024-05-21 | EVOTEC SE: Q1 2024 Earnings Release |
| 2024-06-30 | IMMUNOVANT, INC.: Q4 2024 Earnings Release (Projected) |
| 2024-07-15 01:45 | ADDLIFE AB: Q2 2024 Earnings Release |
| 2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
Past sector events for Lantern Pharma Inc.
| Today | REPLIMUNE GROUP, INC.: Q4 2024 Earnings Release (Projected) |
| 2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
| 2024-05-14 07:30 | ABSCI CORPORATION: Q1 2024 Earnings Release |
| 2024-05-13 | BELITE BIO, INC: Q1 2024 Earnings Release |
| 2024-05-13 | POLARIS GROUP: Q1 2024 Earnings Release |
| 2024-05-13 16:30 | AEROVATE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-13 07:00 | APOGEE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-12 19:00 | PRAXIS PRECISION MEDICINES, INC.: Q1 2024 Earnings Release |
| 2024-05-13 06:30 | FORTREA HOLDINGS INC.: Q1 2024 Earnings Release |
| 2024-05-13 16:10 | CENTESSA PHARMACEUTICALS PLC: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LTRN Stock
- Calendar Lantern Pharma Inc.
